UNSPSC 51342701: Atazanavir

This classification denotes a protease inhibitor with the molecular formula C38H52N6O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QZU4H47A3S, chemically known as 2,5,6,10,13-pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester, (3s,8s,9s,12s)- but generally known as atazanavir, which bears US NIH Compound Identifier 148192. Atazanavir most often comes in base and sulfate forms.

UNSPSC 51342701 Atazanavir is a Commodity code that in state and local procurement appears to span pharmaceutical procurement more broadly, though recent activity shows limited direct solicitation under this specific code. The recent opportunities posted under it reflect acquisitions of emergency medical supplies, pharmaceutical benefit management services, and generic multi-source pharmaceutical products for state health agencies, local fire departments, and cooperative purchasing alliances rather than atazanavir antiretroviral therapy specifically. State and local purchasing departments, county health systems, state health and human services commissions, and multi-jurisdictional cooperative purchasing alliances are the primary issuing bodies, with activity spanning emergency response procurement (medical and first aid supplies for fire rescue), pharmaceutical benefit program development (direct-to-manufacturer prescription initiatives), and statewide generic drug contracting through group purchasing arrangements.

Geographic activity includes Florida (Seminole County), Texas (Texas Health and Human Services Commission), Florida again (City of Tampa), and Minnesota (MMCAP serving multiple states including Oregon). Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (1,900 units annually, due July 26, 2023), the City of Tampa's invitation to bid for medical and first aid supplies for the Fire Department Rescue Division (169 line items, estimated contract value $700,000, with SLBE set-aside and 5% discount, due March 13, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities (proposals due March 26, 2026). The mismatch between the code's nominal scope (atazanavir monotherapy) and the actual procurement activity suggests this code may be misapplied to broader pharmaceutical supply and pharmacy benefit management categories in state and local systems, warranting clarification of the intended commodity before commitment.